Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was ...

Hytale Patch Notes for Update 3 Brings Animal Taming, Map Markers, and Major Overhauls

Check out the latest features introduced in the Hytale patch notes for update 3 including animal taming, map markers and creative hub changes ...

Disc Medicine After The CRL: Risk Now Rests On APOLLO

Disc Medicine stock is hit by an FDA CRL for bitopertin. Learn key trial risks, cash runway, and why APOLLO Phase 3 results ...

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...